MESSAGE BOARD The marketing of mental illness In "Talking back to Prozac," Joshua Kendall profiles British psychiatrist David Healy, who argues that the makers of antidepressants have too much influence on researchers, regulators, and our very definition of mental illness. Have drug companies exaggerated the extent of depression as well as the safety of their products? And if so, what should the Food and Drug Administration do about it? Read the story: Talking back to Prozac Response pages:  1   Name: City/Town: Email: (For confirmation purposes only) Phone: (For confirmation purposes only) Your thoughts:    This week's Ideas section Past Ideas message boards